Idera Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2019 Financial Results
August 08, 2019 09:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera to Release 2019 Second Quarter Results on August 8, 2019
August 06, 2019 16:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera Pharmaceuticals Announces Appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and John J. Kirby as Chief Financial Officer
July 23, 2019 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., July 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the appointments of Elizabeth A. Tarka, MD, FACC as Chief Medical Officer and the promotion...
Idera Pharmaceuticals to Present at the 2019 JMP Securities Life Sciences Conference
June 18, 2019 16:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., June 18, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 2019 JMP Securities Life Sciences Conference on...
Idera Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 02, 2019 16:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., May 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera Pharmaceuticals Provides Corporate Update
April 10, 2019 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 10, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting
April 02, 2019 07:00 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the...
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update
March 06, 2019 16:30 ET
|
Idera Pharmaceuticals, Inc.
– ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 –– ILLUMINATE-204 Enrollment Complete; Data Anticipated Q4 2019 –– ILLUMINATE-206 Trial Expected to Initiate Q2 2019 –– Chief Medical...
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment
February 27, 2019 07:00 ET
|
Idera Pharmaceuticals, Inc.
- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4th Quarter of 2019 – - December 2018 Interim Update of 34 efficacy evaluable patients demonstrated 32.4%...
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
January 04, 2019 07:30 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37th Annual J.P. Morgan Healthcare Conference on...